Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Increased microglial activity and elevated cytokine levels have been demonstrated in patients with ASD (Komada and Nishimura 2022)
Naltrexone, approved in 1984, introduced a non-opioid antagonist that blocked the effects of opioids but required full detoxification before initiation, limiting its early use
Suggest starting from 0.25mg/day, with weekly increments not exceeding 0.25mg, and a maximum dose not exceeding 1mg/day
The Silveira et al
doi: 10.1111/bph.13250 184 LaurikainenH.TuominenL.TikkaM.MerisaariH.ArmioR.-L.SormunenE.et al
US$ 24.91
US$ 25.85
US$ 28.04
